Work

Spatiotemporal patterns and influencing factors of genotypic resistance testing utilization among people living with HIV: A 10-year retrospective analysis at a tertiary care hospital in Beijing, China (2014–2023)

Year: 2025

Type: article

Abstract: Prior research indicated low human immunodeficiency virus (HIV) genotypic resistance testing (GRT) utilization in China due to partial cost coverage under national antiretroviral therapy policies, limited testing accessibility, and financial barriers. Temporal and spatial data on GRT trends were also scarce. We analyzed GRT patterns among 6,895 treated individuals at a tertiary hospital using Joinpoint regression, multivariable logistic modeling, and spatial analysis (GeoDa/SatScan). GRT rates showed a significant two-phase upward trend, increasing from 5.36 % in 2014 to 74.17 % in 2023, with an average annual percen tage change of 31.30 % ( P < 0.001). Beijing residency (adjusted odds ratio [a OR ] = 2.596, 95 % confidence interval [ CI ]: 2.307–2.921) and older age were associated with higher GRT uptake. Specifically, ages 35–44 years (a OR = 1.207, 95 % CI : 1.026–1.420), 45–54 years (a OR = 1.335, 95 % CI : 1.104–1.613), and ≥ 55 years (a OR = 1.424, 95 % CI : 1.126–1.802) had significantly higher odds of testing. Lower testing rates were observed in individuals with lower education (high school or technical secondary: a OR = 0.827; junior high school: a OR = 0.835; primary school: a OR = 0.695), unknown sexually transmitted diseases (STDs) history (a OR = 0.415), and non-heterosexual transmission routes (homosexual: a OR = 0.834). Spatial analysis identified GRT clustering across Beijing until 2021, with two space–time clusters identified in 2019–2023 and 2018–2022. This study demonstrates substantial increase in GRT uptake achieving more balanced district-level distribution since 2021. Age, education, STDs history, and transmission route influence GRT utilization. Improving access, reducing costs, and implementing targeted interventions are needed to optimize testing and guide antiretroviral therapy decisions.

Source: Biosafety and Health

DOI: 10.1016/j.bsheal.2025.05.001